Clinical Use of Artificial Oxygen Carriers

  • N. Dettori
  • R. Kocian
  • D. R. Spahn
Conference paper


Artificial oxygen carriers aim at improving oxygen delivery (DO2). Artificial oxygen carriers, therefore, may be used as an alternative to allogeneic blood transfusions or to improve tissue oxygenation and function of organs with marginal oxygen supply [1, 2]. Modified hemoglobin solutions and perfluorocarbon (PFC) emulsions are currently undergoing clinical testing. This chapter is based on a recent review article [3] where more detailed references may be found. Current knowledge of artifical oxygen carriers is based on published data from approximately 500–1000 patients treated with these compounds and a similar number of control patients. Unfortunately, there is still a significant amount of non-published data that renders the overall assessment of these solutions difficult.


Autologous Blood Oxygen Carrier Allogeneic Blood Transfusion Blood Substitute Hemoglobin Solution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Spahn DR, Pasch T (2001) Physiological properties of blood substitutes. News Physiol Sci 16: 38–41PubMedGoogle Scholar
  2. 2.
    Winslow RM (2000) Blood substitutes. Advanced Drug Delivery Reviews 40: 131–142PubMedCrossRefGoogle Scholar
  3. 3.
    Spahn DR, Kocian R (2003) Place of artifical oxygen carriers in reducing allogeneic blood transfusions and augmenting tissue oxygenation. Can J Anaesth (in press)Google Scholar
  4. 4.
    Stowell CP, Levin J, Spiess BD, Winslow RM (2001) Progress in the development of RBC substitutes. Transfusion 41: 287–299PubMedCrossRefGoogle Scholar
  5. 5.
    Viele MK, Weiskopf RB, Fisher D (1997) Recombinant human hemoglobin does not affect renal function in humans: analysis of safety and pharmacokinetics. Anesthesiology 86: 848–858PubMedCrossRefGoogle Scholar
  6. 6.
    Winslow RM (2000) Alpha-alpha-crosslinked hemoglobin: was failure predicted by preclinical testing? Vox Sang 79: 1–20PubMedCrossRefGoogle Scholar
  7. 7.
    Sloan EP, Koenigsberg M, Gens D, et al (19999) Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 282: 1857–1864Google Scholar
  8. 8.
    Lamy ML, Daily EK, Brichant J-F, et al (2000) Randomized trial of Diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. Anesthesiology 92: 646–656PubMedCrossRefGoogle Scholar
  9. 9.
    Gould SA, Moore EE, Hoyt DB, et al (1998) The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 187: 113–120PubMedCrossRefGoogle Scholar
  10. 10.
    Carmichael FJ, Biro GP, Cheng DC (2001) Phase III clinical trial of hemolink in conjunction with intraoperative autologous donation (IAD) in cardiac surgical patients. Artif Cells Blood Substit Immobil Biotechnol 29: 102 (abst)Google Scholar
  11. 11.
    Jahr JS (2001) A novel blood substitute: Use of HBOC-201 (Hemopure) to decrease need for RBC: Results of pivotal trail in orthopedic surgery patients. Crit Care Med 29 (suppl): A160 (abst)Google Scholar
  12. 12.
    Levy JH, Goodnough LT, Greilich P, et al (2002) Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 124: 35–42PubMedCrossRefGoogle Scholar
  13. 13.
    Cheng DC, Martineau R, MacAdams C, et al (2001) Safety of Hemolink as an oxygen therapeutic in patients undergoing coronary artery bypass graft surgery. Anesth Analg 92 (suppl):SCA3 (abst)Google Scholar
  14. 14.
    Jahr JS, Stewart LM, MacKenzie C, Bourke D, williams JP (2002) Pivotal phase III study: safety of polymerized bovine hemoglobin (HBOC-201, Hemopure) as compared to RBC in patients undergoing orthopedic surgery. Anesthesiology 96: A243 (abst)Google Scholar
  15. 15.
    Sprung J, Kindscher JD, Wahr JA, et al (2002) The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study. Anesth Analg 94: 799–808PubMedCrossRefGoogle Scholar
  16. 16.
    Riess JG (2001) Oxygen carriers (“Blood substitutes”)–raison d’etre, chemistry, and some physiology. Chem Rev 101: 2797–2920PubMedCrossRefGoogle Scholar
  17. 17.
    Keipert PE, Faithfull NS, Bradley JD, et al (1994) Oxygen delivery augmentation by low-dose perfluorochemical emulsion during profound normovolemic hemodilution. Adv Exp Med Biol 345: 197–204PubMedCrossRefGoogle Scholar
  18. 18.
    Spahn DR, van Bremt R, Theilmeier G, et al (1999) Perflubron emulsion delays blood transfusion in orthopedic surgery. Anesthesiology 91: 1195–1208PubMedCrossRefGoogle Scholar
  19. 19.
    Frumento RJ, Mongero LM, Naka Y, Bennett Guerrero E (2002) Preserved gastric tono-metric variables in cardiac surgical patients administered intravenous perflubron emulsion. Anesth Analg 94: 809–814PubMedCrossRefGoogle Scholar
  20. 20.
    Spahn DR, Waschke K, Standl T, et al (2002) Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 96: 1338–1349CrossRefGoogle Scholar
  21. 21.
    Looker D, Abbott-Brown D, Cozart P, et al (1992) A human recombinant haemoglobin designed for use as a blood substitute. Natue 356: 258–260CrossRefGoogle Scholar
  22. 22.
    Spahn DR (1999) Blood substitutes: artifical oxygen carriers: perfluorocarbon emulsions. Crit Care 3: R93 - R97PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • N. Dettori
  • R. Kocian
  • D. R. Spahn

There are no affiliations available

Personalised recommendations